US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.1316970044905683,
        "turnoverUsdM": 1680.653161647794,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1110.8443,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.3,
      "take_profit_price": 1244.3234,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 5
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.263394008981137,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 47.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 1186.8755,
    "ma50": 1125.2808,
    "close": 1185.07,
    "prevClose": 1163.01,
    "avgVolume20": 2820998,
    "volumeRatio": 0.5,
    "changePercent": 1.9
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.013599310156801492,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.4897909888292632,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.273562985235843,
      "volat_points": 2,
      "day_range_pct": 0.040343559602852415,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 6.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 45.33,
        "contribution": 6.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 17.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59,
        "contribution": 17.7
      },
      {
        "raw": 1,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 10,
        "contribution": 1
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 47.6,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 6.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 17.7/30分",
      "情緒分析: 1/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 8.4,
      "市場環境": 6.8,
      "情緒分析": 1,
      "技術信號": 17.7,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 1680.653161647794,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 0.8,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.64
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 713.3184992500002,
                "ma50": 718.7466015999998,
                "name": "QQQ",
                "close": 691.91998,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.92100485,
                "ma50": 745.0528012400001,
                "name": "SPY",
                "close": 738.16998,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.1316970044905683,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 1,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 3,
              "positiveHits": 2,
              "sentimentScoreRaw": -0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140994624,
                "url": "https://finnhub.io/api/news?id=a128be632149988299adc1fe9cacb82f55defe5853819b35c97ee3dee9932d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...",
                "category": "company",
                "datetime": 1784819722,
                "headline": "How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story"
              },
              {
                "id": 140991785,
                "url": "https://finnhub.io/api/news?id=a78be83fdf06a774980bf42e0ece428594a4d4dc39e9c1bc1738bddae85cff76",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows strong growth with 113% EPS growth and a bullish technical breakout setup, earning 9/10 ratings for both fundamentals and chart pattern.",
                "category": "company",
                "datetime": 1784799630,
                "headline": "Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup"
              },
              {
                "id": 140983019,
                "url": "https://finnhub.io/api/news?id=c3c43c401f44116db2170f2c44b2f94a1c0eaf7be37797d8b20b550f6d4aed9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.",
                "category": "company",
                "datetime": 1784731320,
                "headline": "NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140977644,
                "url": "https://finnhub.io/api/news?id=4218cab00fc1d9a327129391ab2f1b3d97a54d46c0db770e5c6cc09f29353025",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...",
                "category": "company",
                "datetime": 1784675656,
                "headline": "Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?"
              },
              {
                "id": 140973259,
                "url": "https://finnhub.io/api/news?id=93053a6dafdc3936b236bd0d8c08abe9a30a83776cd88812bb68f6b6d7ce6d71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has gained 8.4%.",
                "category": "company",
                "datetime": 1784649026,
                "headline": "Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140971572,
                "url": "https://finnhub.io/api/news?id=aaf4dc4f37d7c1738bb337979f6ad887b695b104a5e86c33f46a813bafc70219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmakers clash over marketing of blockbuster obesity and diabetes treatmentsNovo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.",
                "category": "company",
                "datetime": 1784641847,
                "headline": "Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle (NVO, LLY)"
              },
              {
                "id": 140966202,
                "url": "https://finnhub.io/api/news?id=3d9813fceba3cf5e2cd0c0d79b98773b1e68786cdc6c96489fa8468aba8b674d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...",
                "category": "company",
                "datetime": 1784585555,
                "headline": "Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI"
              }
            ],
            "raw_source": [
              {
                "id": 140997601,
                "url": "https://finnhub.io/api/news?id=9a7c5197d026eae722976256cb490cd81623c46e49ec64717db7313e4a8094ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.",
                "category": "company",
                "datetime": 1784830680,
                "headline": "Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum"
              },
              {
                "id": 140997602,
                "url": "https://finnhub.io/api/news?id=dcb90ca8738804304b4720e09b8a9a9fe7682c5918c5e1fb3833f6ce4674848b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.",
                "category": "company",
                "datetime": 1784828301,
                "headline": "There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders"
              },
              {
                "id": 140997603,
                "url": "https://finnhub.io/api/news?id=8aaf90a0055946157928aaaa976b080f50916599f7ffcba9609c4e9fab0a4b4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Two more Phase 3 trials showed weight loss above 20%",
                "category": "company",
                "datetime": 1784826801,
                "headline": "Lilly Targets Early 2027 Filing for Next Obesity Drug"
              },
              {
                "id": 140997604,
                "url": "https://finnhub.io/api/news?id=7b9d30d4c4091626ac26fbb2dc3e80caa5201f491007b479a434b4b5af03ce3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Retatrutide delivered substantial weight loss in two additional late-stage trials.",
                "category": "company",
                "datetime": 1784826645,
                "headline": "Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing"
              },
              {
                "id": 140997605,
                "url": "https://finnhub.io/api/news?id=7e5d80e67c6d1a9459c3bce7668de08472da0c3ae72ce8de417b55033c38e8c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmaker  Eli Lilly  said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year.  Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off.  Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.",
                "category": "company",
                "datetime": 1784823840,
                "headline": "Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027"
              },
              {
                "id": 140994623,
                "url": "https://finnhub.io/api/news?id=d16681bea87a6c620037072934ddd19c62b77d701ddb423dc87133e19ef199ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators.",
                "category": "company",
                "datetime": 1784820163,
                "headline": "Lilly to file for next-gen obesity drug approval in early 2027"
              },
              {
                "id": 140994624,
                "url": "https://finnhub.io/api/news?id=a128be632149988299adc1fe9cacb82f55defe5853819b35c97ee3dee9932d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...",
                "category": "company",
                "datetime": 1784819722,
                "headline": "How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story"
              },
              {
                "id": 140994625,
                "url": "https://finnhub.io/api/news?id=86ea9dd4ef833438bd7fe5e9ffe85939adc80cda913f0390326517f45bf4d02d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.",
                "category": "company",
                "datetime": 1784817738,
                "headline": "Another win for Lilly’s triple-g agonist in two more Phase III trials"
              },
              {
                "id": 140994626,
                "url": "https://finnhub.io/api/news?id=22df39746c7745426510628b0dd3e7976822ef0451fff3c063ba6b93d5addb6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.",
                "category": "company",
                "datetime": 1784815920,
                "headline": "How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?"
              },
              {
                "id": 140996690,
                "url": "https://finnhub.io/api/news?id=85af9e8893acc6773c696c8ffbce2fa38f27f38ee6fd643adf77b9f3130959f1",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784813736,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140993199,
                "url": "https://finnhub.io/api/news?id=1e1dcde38b10d200c988610b782f0e840f7cf8f05ba9c867262a78abb2f4d942",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.",
                "category": "company",
                "datetime": 1784811900,
                "headline": "Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know."
              },
              {
                "id": 140993327,
                "url": "https://finnhub.io/api/news?id=cc7eb5954b2304db65d535608c2266717c11c4d3d15590a1c8a922bcbd5bdac9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.",
                "category": "company",
                "datetime": 1784809395,
                "headline": "Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing"
              },
              {
                "id": 140994627,
                "url": "https://finnhub.io/api/news?id=79dd45d94c59a069cd283e39bad622b0a875c167db9522f4bc04cf6e1ee8e544",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.",
                "category": "company",
                "datetime": 1784806895,
                "headline": "Lilly, with new data, to seek FDA approval of obesity drug retatrutide"
              },
              {
                "id": 140993328,
                "url": "https://finnhub.io/api/news?id=6823179c17dba300c1c40589f478e730f416a20cb6cb32b0e76fa68c52c5cb64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.",
                "category": "company",
                "datetime": 1784803680,
                "headline": "Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data"
              },
              {
                "id": 140992499,
                "url": "https://finnhub.io/api/news?id=e45b55ad179ab6476d3c8b30b375a2d7cd90f26a20784c8a863bac2b1f401ca9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and establis",
                "category": "company",
                "datetime": 1784803500,
                "headline": "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C"
              },
              {
                "id": 140991785,
                "url": "https://finnhub.io/api/news?id=a78be83fdf06a774980bf42e0ece428594a4d4dc39e9c1bc1738bddae85cff76",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows strong growth with 113% EPS growth and a bullish technical breakout setup, earning 9/10 ratings for both fundamentals and chart pattern.",
                "category": "company",
                "datetime": 1784799630,
                "headline": "Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup"
              },
              {
                "id": 140996713,
                "url": "https://finnhub.io/api/news?id=ffba3497dd1ecae3d5b31c52d08ca5f1c925c7328701553b9ae8fae28647e3bb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned for 2027.",
                "category": "company",
                "datetime": 1784797207,
                "headline": "Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits"
              },
              {
                "id": 140995857,
                "url": "https://finnhub.io/api/news?id=948af664a91f1ed7d0e8f105167e55fa50b154364931d9f703d70f73a6ac3559",
                "image": "https://image.cnbcfm.com/api/v1/image/108330310-1783027295728-gettyimages-2284381414-_m0a2793_xi38wxwr.jpeg?v=1783027486&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1784792063,
                "headline": "Stocks making the biggest moves premarket: Lockheed Martin, Tesla, Alphabet & more"
              },
              {
                "id": 140996714,
                "url": "https://finnhub.io/api/news?id=e4437449a4ed459de0cf3a1486f7943e1ec99f5632f30cf520c7a1c8b6a64a7c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating",
                "category": "company",
                "datetime": 1784789311,
                "headline": "Eli Lilly Reports Topline Results From TRIUMPH-2 And TRIUMPH-3 Phase 3 Trials Evaluating Retatrutide; Treatment Met Primary Endpoint, With Substantial Weight Loss In Adults With Obesity"
              },
              {
                "id": 140995874,
                "url": "https://finnhub.io/api/news?id=e83cb9df1fdd4022d376515ac192a92b16cfbc1d774c5b7524b0b2f824fe1cd7",
                "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1779898152&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.",
                "category": "company",
                "datetime": 1784789102,
                "headline": "Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials"
              },
              {
                "id": 140991356,
                "url": "https://finnhub.io/api/news?id=4d840276aeb0d6f1dfb2fa943380324e66e059bacf6629b0c8603290a23fb52d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]",
                "category": "company",
                "datetime": 1784787517,
                "headline": "Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline"
              },
              {
                "id": 140997606,
                "url": "https://finnhub.io/api/news?id=ce69505dde9c2aa7483984a1a158e4307eff9fe773f140fbefc671155f13219d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.",
                "category": "company",
                "datetime": 1784779260,
                "headline": "Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts"
              },
              {
                "id": 140984714,
                "url": "https://finnhub.io/api/news?id=bd326c72d5b48fc9d87d6488a1fdb496e6a1b97eafbc9571a0ac45ae8cb1bbd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.",
                "category": "company",
                "datetime": 1784737521,
                "headline": "The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side"
              },
              {
                "id": 140983019,
                "url": "https://finnhub.io/api/news?id=c3c43c401f44116db2170f2c44b2f94a1c0eaf7be37797d8b20b550f6d4aed9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.",
                "category": "company",
                "datetime": 1784731320,
                "headline": "NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now"
              },
              {
                "id": 140983020,
                "url": "https://finnhub.io/api/news?id=17e5f2ca7d54253b692081f105ffa61e3c91f2aa5224d83d41d26dc1977763f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's expanding GLP-1 portfolio and pipeline remain in focus as demand stays strong ahead of its second-quarter earnings results.",
                "category": "company",
                "datetime": 1784730180,
                "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Costco Wholesale, Morgan Stanley and Kewaunee Scientific"
              },
              {
                "id": 140983021,
                "url": "https://finnhub.io/api/news?id=a6f7d48efa7ce55737dec470f4e6523b6d251d05fec3840ffe8d744b0cbe11b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
                "category": "company",
                "datetime": 1784728800,
                "headline": "Lilly confirms date and conference call for second-quarter 2026 financial results announcement"
              },
              {
                "id": 140983022,
                "url": "https://finnhub.io/api/news?id=c4fa2481b4dffac5d9a26a33c9dc996570ab15065375f16241046649efd8ada1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.",
                "category": "company",
                "datetime": 1784728320,
                "headline": "NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140986284,
                "url": "https://finnhub.io/api/news?id=b2972b986cf129ebe0edfdde09e818d798a762dbd2019e1a121090c7ee499dfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
                "category": "company",
                "datetime": 1784723911,
                "headline": "What You Need to Know Ahead of Eli Lilly's Earnings Release"
              },
              {
                "id": 140983761,
                "url": "https://finnhub.io/api/news?id=96be1c9a57931cb47d1e6d9d1241589e4644addd7b819db5dfae61b589c0610f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690121/image_1340690121.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions.",
                "category": "company",
                "datetime": 1784723700,
                "headline": "Nomura Core Equity Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 140980884,
                "url": "https://finnhub.io/api/news?id=856013786cfee49180836033d17881b78a32c41bd368c8856e103108e23f0a3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body count. Here is where he says the smart money is quietly moving before the damage hits.",
                "category": "company",
                "datetime": 1784715732,
                "headline": "“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits"
              },
              {
                "id": 140980977,
                "url": "https://finnhub.io/api/news?id=7a6528725d9c46a032b9aec4860fb2d1d0620a931ee06da19f7676b4d8235c80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in \"Hallucinating Value: Healthcare's AI Narrative.\"",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown"
              },
              {
                "id": 140981530,
                "url": "https://finnhub.io/api/news?id=6b6018e5672410183893a1ef8edd7db31fdb8f487a6c07dee7f72e0f18122db2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283703169/image_2283703169.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1784712513,
                "headline": "Novartis: The Buy Thesis Is Back (Rating Upgrade)"
              },
              {
                "id": 140980672,
                "url": "https://finnhub.io/api/news?id=50b58c922e0c9aa926f433602a29e8525b738056a0af77e107d9574d4d195a28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1828680033/image_1828680033.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Super Micro rockets higher. The clock is ticking for generic drug imports. Nike's China strategy shift.",
                "category": "company",
                "datetime": 1784703600,
                "headline": "Wall Street Breakfast Podcast: Super Micro Heats Up"
              },
              {
                "id": 140984715,
                "url": "https://finnhub.io/api/news?id=69b3009beac273383d7deed0ef8929b415ffa5502aa6bbc8db8f10fdded798f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish pharma giant alleged Lilly misled consumers with false advertising claims that its weight loss drug is superior to Novo’s.",
                "category": "company",
                "datetime": 1784692860,
                "headline": "Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims"
              },
              {
                "id": 140977644,
                "url": "https://finnhub.io/api/news?id=4218cab00fc1d9a327129391ab2f1b3d97a54d46c0db770e5c6cc09f29353025",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...",
                "category": "company",
                "datetime": 1784675656,
                "headline": "Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?"
              },
              {
                "id": 140977645,
                "url": "https://finnhub.io/api/news?id=2f7b4f601dcf7f7dd0037826b05db3c67ac340ce3f2b40cb72795ee87c41e6af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it more cautiously than the fundamentals imply. Over the past 3 years, Novo Nordisk has delivered a total shareholder return that is down 35.8%, which puts the recent share price in the context of a material drawdown for long term holders. Expectations around the obesity and diabetes franchise, including products such as Wegovy, sit alongside legal and...",
                "category": "company",
                "datetime": 1784672152,
                "headline": "Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak"
              },
              {
                "id": 140976254,
                "url": "https://finnhub.io/api/news?id=d312544c2126879586c6f841dd51947659f186109d11c9e56902a50eb9c0ea81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.",
                "category": "company",
                "datetime": 1784670841,
                "headline": "\"Deceptive Advertising!\" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks."
              },
              {
                "id": 140976347,
                "url": "https://finnhub.io/api/news?id=2d7dd2b1278139b412662c287ad311d6d5433b1ffa75133d854ac78f9065fe62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly , accusing its arch-rival of misleading advertising.",
                "category": "company",
                "datetime": 1784669115,
                "headline": "Novo accuses rival Eli Lilly of \"deceptive\" weight-loss drug ads"
              },
              {
                "id": 140976348,
                "url": "https://finnhub.io/api/news?id=a56eb6977a8dbdf25a1c0af3adf0fdb78a9d0a5fa51fe905fa0d496203557c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.",
                "category": "company",
                "datetime": 1784664300,
                "headline": "Top Research Reports for Eli Lilly, Costco & Morgan Stanley"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974895,
                "url": "https://finnhub.io/api/news?id=1ac5caa10a21ca147aa3006cba72e0bc0f153d7e70b3a4dc4eb91f33349c26f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the",
                "category": "company",
                "datetime": 1784662859,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 140974896,
                "url": "https://finnhub.io/api/news?id=db6cdd51ed994892da17837a3314c0ba5404d44f284cc0305ce2609a9abb9653",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit:: July 21, 2026:: Maggie Fick, European Pharma Industry Correspondent\"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs.\" //\"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines.\"\"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common.\"\"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill.\"\"Both companies report quarterly results in the next couple of weeks.\":: Novo Nordisk:: Eli LillyThe Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.",
                "category": "company",
                "datetime": 1784660210,
                "headline": "Novo sues Lilly, claiming misleading ads in weight-loss drug battle"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140973254,
                "url": "https://finnhub.io/api/news?id=7cca9487422533579c49e732eec72b53588140d7206136df59fb6cb6c55fb443",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the",
                "category": "company",
                "datetime": 1784654979,
                "headline": "Sector Update: Healthcare Stocks Advance Tuesday Afternoon"
              },
              {
                "id": 140973255,
                "url": "https://finnhub.io/api/news?id=aeef7ea0bf4b894c0a43a6d095635fa719538fec9a31edf51e60bd2511684e6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged \"misleading\" adverti",
                "category": "company",
                "datetime": 1784652076,
                "headline": "Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns"
              },
              {
                "id": 140973256,
                "url": "https://finnhub.io/api/news?id=29abcc8d0e94596aa56202324ee49811dd698588001a65834e415155cce0c1f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.",
                "category": "company",
                "datetime": 1784650954,
                "headline": "Novo sues Lilly after alleged misleading and false advertising campaign"
              },
              {
                "id": 140973257,
                "url": "https://finnhub.io/api/news?id=905818d80fb6e3574711e60f78c49f15c8476f086ace982f0077aec934669ff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu",
                "category": "company",
                "datetime": 1784650610,
                "headline": "Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising"
              },
              {
                "id": 140973258,
                "url": "https://finnhub.io/api/news?id=f28be650fad11e9188136404e95cbffcab5b25d4d2692a379e454692be8b6907",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The European markets closed higher Tuesday as tech, bank, and mining stocks rallied, while investors",
                "category": "company",
                "datetime": 1784649329,
                "headline": "European Stocks Close Higher in Tuesday Trading; Investors Await ECB Rate Decision"
              },
              {
                "id": 140973259,
                "url": "https://finnhub.io/api/news?id=93053a6dafdc3936b236bd0d8c08abe9a30a83776cd88812bb68f6b6d7ce6d71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has gained 8.4%.",
                "category": "company",
                "datetime": 1784649026,
                "headline": "Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140971564,
                "url": "https://finnhub.io/api/news?id=1bf4a57be3dd22914964e340811aa40d739283a736d914beccd336aa57b7e604",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so",
                "category": "company",
                "datetime": 1784648948,
                "headline": "Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising"
              },
              {
                "id": 140971565,
                "url": "https://finnhub.io/api/news?id=53dcca44de39d5d13badd71f5cd9329b9f05fe72a89744eca707919c05e2d8d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Danish drugmaker alleges Lilly used outdated trial data to claim Zepbound beats Wegovy on weight loss",
                "category": "company",
                "datetime": 1784648036,
                "headline": "Novo Sues Lilly Over Weight-Loss Ad Claims"
              },
              {
                "id": 140971566,
                "url": "https://finnhub.io/api/news?id=65db53db472672696d2d7c3105ced46e7287d590f51bb699fe60ed1a6f1a963f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District...",
                "category": "company",
                "datetime": 1784647080,
                "headline": "Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims"
              },
              {
                "id": 140971567,
                "url": "https://finnhub.io/api/news?id=65efb07d7073290eeadfbe8738f5f22b9148c48c2206a9154393113014efd1ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.",
                "category": "company",
                "datetime": 1784644740,
                "headline": "Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know"
              },
              {
                "id": 140971568,
                "url": "https://finnhub.io/api/news?id=250f7bb1c408461b9f8a9a95386cf448cfdd0c8361cb1b37ca741e7574a7b4ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.",
                "category": "company",
                "datetime": 1784644521,
                "headline": "Novo Nordisk sues Eli Lilly, accusing it of false advertising"
              },
              {
                "id": 140971569,
                "url": "https://finnhub.io/api/news?id=5701eb8be606782bc395b4ab1b0885a0b3231ec27c98d93ec8e17f582eababa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.",
                "category": "company",
                "datetime": 1784644140,
                "headline": "Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising"
              },
              {
                "id": 140971570,
                "url": "https://finnhub.io/api/news?id=1c2b2002589f59ce4729d3d6d1b74566f8ad65240e433d0f85304bedcb57fbea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.",
                "category": "company",
                "datetime": 1784643420,
                "headline": "GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk"
              },
              {
                "id": 140971571,
                "url": "https://finnhub.io/api/news?id=5b77ab39182f5f6397ac13467d36a191807a0013444eb2254cf52e9273455cca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne.",
                "category": "company",
                "datetime": 1784642462,
                "headline": "Weight-loss wars: Why Novo Nordisk is suing Eli Lilly"
              },
              {
                "id": 140971572,
                "url": "https://finnhub.io/api/news?id=aaf4dc4f37d7c1738bb337979f6ad887b695b104a5e86c33f46a813bafc70219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmakers clash over marketing of blockbuster obesity and diabetes treatmentsNovo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.",
                "category": "company",
                "datetime": 1784641847,
                "headline": "Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle (NVO, LLY)"
              },
              {
                "id": 140970419,
                "url": "https://finnhub.io/api/news?id=1d3a98d8166e1d62fe31e1a36ca7e485d7b3b78c5e3ba3536eef57d2d2cefba2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over \"false and materially misleading\" adverts for their competing weight-loss and anti-diabetes treatments. Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide.",
                "category": "company",
                "datetime": 1784638794,
                "headline": "Pharma heavyweights clash over anti-obesity drug ads"
              },
              {
                "id": 140970420,
                "url": "https://finnhub.io/api/news?id=faef8396042d8c8ca053b4159333a0762ceec68b12fabc099fd567744019bc60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.",
                "category": "company",
                "datetime": 1784638298,
                "headline": "Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads"
              },
              {
                "id": 140972831,
                "url": "https://finnhub.io/api/news?id=9998884f56a979486db43d0796f74bc7aa47567d33055de61814f7a36f6877cb",
                "image": "https://image.cnbcfm.com/api/v1/image/108338007-17846520361784652033-47303621411-1080pnbcnews.jpg?v=1784652035&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The Investment Committee debate some of their stocks that are moving today.",
                "category": "company",
                "datetime": 1784637874,
                "headline": "Committee stocks on the move: Eli Lilly, D.R. Horton, SpaceX and Live Nation"
              },
              {
                "id": 140970421,
                "url": "https://finnhub.io/api/news?id=03bf594974cadcbdde2a8f7e30526e4e2515e9a990806faeecc9b2fb59fbe453",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb",
                "category": "company",
                "datetime": 1784636398,
                "headline": "Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud"
              },
              {
                "id": 140970422,
                "url": "https://finnhub.io/api/news?id=1d8f6535cc184536362666620d37f4fcff10a91ffcee247fd0a2e0271f66c310",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.",
                "category": "company",
                "datetime": 1784635545,
                "headline": "Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads"
              },
              {
                "id": 140970423,
                "url": "https://finnhub.io/api/news?id=746aee4cae4e29afaba580b12f048634073e4479976f7b58bf986e5b9d9bfbaf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.",
                "category": "company",
                "datetime": 1784635080,
                "headline": "Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly"
              },
              {
                "id": 140969462,
                "url": "https://finnhub.io/api/news?id=8997d9a68a10f6e74d8e038102dea334f9ec13c4c35c96be0f36f32a0804fcc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections",
                "category": "company",
                "datetime": 1784634723,
                "headline": "Novo Nordisk sues Eli Lilly over misleading weight loss drug ads"
              },
              {
                "id": 140970424,
                "url": "https://finnhub.io/api/news?id=2e6740fd37fcee2c66fbdf6503b2fcc1070ab2f216641494387bf05a556fdbcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor",
                "category": "company",
                "datetime": 1784634626,
                "headline": "Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads"
              },
              {
                "id": 140969463,
                "url": "https://finnhub.io/api/news?id=75302f3772a8070817b6057db89f750a8aaf08892335b4a8a3680860719ec4b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...",
                "category": "company",
                "datetime": 1784633760,
                "headline": "Novo Nordisk accuses Eli Lilly of deceptive marketing in weight-loss fight"
              },
              {
                "id": 140969464,
                "url": "https://finnhub.io/api/news?id=2ff846dfada1566f1e4b24f0b0fbb17b4d2d3bc4fa6a7685221ec97b44e5cc30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against lower doses of Novo Nordisk's injectable medicines for obesity and type 2 diabetesThese high-profile US advertising campaigns create the misleading impression that Lilly’s medicines are superior, including by withholding critical scientific evidence about newer, more effective FDA-",
                "category": "company",
                "datetime": 1784633700,
                "headline": "Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly"
              },
              {
                "id": 140974172,
                "url": "https://finnhub.io/api/news?id=169f8da3bf17dd19ac1abbd97989e1744ef1415c756128b80432a294ab91a7d2",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Reuters",
                "category": "company",
                "datetime": 1784630647,
                "headline": "Eli Lilly On Novo Nordisk Lawsuit, Says \"We Stand Firmly Behind Our Advertising\"; We Will Continue To Focus On The Science And Defend Against Novo Nordisk Lawsuit Vigorously; Rather Than Compete On The Merits Of Its Products, Novo Is Asking Court To Stop Lilly From Communicating Results Of That Trial"
              },
              {
                "id": 140974173,
                "url": "https://finnhub.io/api/news?id=784d431219287d39dbb8cc8782acc6178638ee786e997fd2e6da8f627146cb2d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Weight-loss-lawsuits.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.",
                "category": "company",
                "datetime": 1784629664,
                "headline": "Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising"
              },
              {
                "id": 140972832,
                "url": "https://finnhub.io/api/news?id=5dca2b4f83a7ebe0229170c50319eda255969a6b176d5b5faa61105db3e384af",
                "image": "https://image.cnbcfm.com/api/v1/image/108337893-17846416031784641600-47301177834-1080pnbcnews.jpg?v=1784641602&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1784627937,
                "headline": "Cramer’s Mad Dash: Eli Lilly"
              },
              {
                "id": 140970425,
                "url": "https://finnhub.io/api/news?id=c5d975e3a6da276348f1132772f534ed7900abab4fcf05fcf3aea20d91aefd65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.",
                "category": "company",
                "datetime": 1784625838,
                "headline": "Beyond weight loss: Lilly aims for leadership in brain science"
              },
              {
                "id": 140974174,
                "url": "https://finnhub.io/api/news?id=5dcd15d27947c91a39a943ea845ed7e81570a3a712285a6d814b5f1f30ecdeec",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli LillyA lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses",
                "category": "company",
                "datetime": 1784619742,
                "headline": "Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising Campaigns"
              },
              {
                "id": 140972833,
                "url": "https://finnhub.io/api/news?id=62b38c69da926ad0682e39a7b798688b323e431d8655822360a306de9706c8bb",
                "image": "https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Novo asked the court to permanently stop Lilly from running the \"deceptive\" ads and require the drugmaker to issue corrective advertising.",
                "category": "company",
                "datetime": 1784619346,
                "headline": "Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising"
              },
              {
                "id": 140969465,
                "url": "https://finnhub.io/api/news?id=1b34e6be29cc89ee95fc326d2194f47a17c3e7b5ff5a00519769067076ecd27d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...",
                "category": "company",
                "datetime": 1784606430,
                "headline": "Psychedelic drugs are going mainstream"
              },
              {
                "id": 140966202,
                "url": "https://finnhub.io/api/news?id=3d9813fceba3cf5e2cd0c0d79b98773b1e68786cdc6c96489fa8468aba8b674d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...",
                "category": "company",
                "datetime": 1784585555,
                "headline": "Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI"
              },
              {
                "id": 140966203,
                "url": "https://finnhub.io/api/news?id=1452c1869014b6b433e26965f1d74215469d6bc9f3c57b5e9c9eeb36f9d9df9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Donald Trump recently praised Eli Lily at a public event and called it “a great company” and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY). Claude AI said […]",
                "category": "company",
                "datetime": 1784584968,
                "headline": "Claude AI Disagrees With President Trump on Eli Lilly (LLY)"
              },
              {
                "id": 140966204,
                "url": "https://finnhub.io/api/news?id=7f2c907390b8838692356a0fabec76d8aebd3d9b5dcc83121dc03dd9efc912a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.",
                "category": "company",
                "datetime": 1784583906,
                "headline": "Here's Why Eli Lilly (LLY) Fell More Than Broader Market"
              },
              {
                "id": 140964862,
                "url": "https://finnhub.io/api/news?id=c32d8e14612b49c61afd688e00df609f03b2a8d835d88092db70f594f6df9aac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.",
                "category": "company",
                "datetime": 1784577602,
                "headline": "Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase"
              },
              {
                "id": 140963402,
                "url": "https://finnhub.io/api/news?id=572d40f14f1b492f6e45585c523e13a6ab5e38d1367d2cea2035434ec4089ff2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t",
                "category": "company",
                "datetime": 1784575650,
                "headline": "Sector Update: Healthcare Stocks Fall Late Afternoon"
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963313,
                "url": "https://finnhub.io/api/news?id=a84e85e25284b1b21f06d40715163bf0e20d0344ecae4ab283e99b44fc5db455",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.",
                "category": "company",
                "datetime": 1784572200,
                "headline": "Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?"
              },
              {
                "id": 140962784,
                "url": "https://finnhub.io/api/news?id=1867da7d02812b87cf8dcf301fdaf9d9703a244c1c79a27133b08cd620c401cf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305424/image_2158305424.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk shares have rallied approximately 27%, driven by accelerating commercial momentum behind Oral Wegovy. Read more on NVO stock here.",
                "category": "company",
                "datetime": 1784558856,
                "headline": "Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum"
              },
              {
                "id": 140960592,
                "url": "https://finnhub.io/api/news?id=87bfd39ebb959bc43097f4456ea6b094616b0e6e95837584dbc90e6f99fc6a59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.",
                "category": "company",
                "datetime": 1784555460,
                "headline": "Does EU Approval of Wegovy Pill Change NVO's Competitive Story?"
              },
              {
                "id": 140960593,
                "url": "https://finnhub.io/api/news?id=9bfd5c4ae79e98761d0c967d32df1b802b93fb69b902d7651862ed0c30b54b0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784552405,
                "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140960594,
                "url": "https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?",
                "category": "company",
                "datetime": 1784551980,
                "headline": "Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"
              },
              {
                "id": 140959485,
                "url": "https://finnhub.io/api/news?id=caa721f340bbedb22a8e1f629ec48c39bebbd8df41106b2c1e3886e03dc1aeeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.",
                "category": "company",
                "datetime": 1784550548,
                "headline": "ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside"
              },
              {
                "id": 140959486,
                "url": "https://finnhub.io/api/news?id=0ac7bdf9b054c901569f5a3e9494d7e069264d131cc96da0afbfca9ffc8853d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on",
                "category": "company",
                "datetime": 1784540720,
                "headline": "‘Wild West’ of Untested Peptides Has Americans Paying in Crypto to Get Their Fix"
              },
              {
                "id": 140957134,
                "url": "https://finnhub.io/api/news?id=834955efcf3e0dfc6dd4efe7dbacc37aa4b93759005bff1d4df145b75988dac0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.",
                "category": "company",
                "datetime": 1784524695,
                "headline": "ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders"
              },
              {
                "id": 140956721,
                "url": "https://finnhub.io/api/news?id=4ec9c4508436a11a03dd62031182d629592016312c096aa5359e5fdd8add4abc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.",
                "category": "company",
                "datetime": 1784519541,
                "headline": "Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?"
              },
              {
                "id": 140955502,
                "url": "https://finnhub.io/api/news?id=cbd0d7c6741205fab274c431ed86e67fa2eee1cf1b7b8cfcc5cfdc8cecd90bad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Maybe you should, too.",
                "category": "company",
                "datetime": 1784499600,
                "headline": "Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140951186,
                "url": "https://finnhub.io/api/news?id=80fc5a8e8ab67c57a31e836e926f232d8209eea2df7399f0f39be6109a2c9017",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1177165160/image_1177165160.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "We share our methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. Read the full list of picks here.",
                "category": "company",
                "datetime": 1784448900,
                "headline": "Our Top 10 High Growth Dividend Stocks - July 2026"
              },
              {
                "id": 140949509,
                "url": "https://finnhub.io/api/news?id=5fb9d2f14f8e04e052f30306d2cdfae47b8641f0181a82e7503118398ea08c1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...",
                "category": "company",
                "datetime": 1784434501,
                "headline": "Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings"
              },
              {
                "id": 140946921,
                "url": "https://finnhub.io/api/news?id=9d3b43a29e84b5e519e515c72dbb2d5e62c0b424a0778946e11db185883228a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Viking's latest program seeks to push the envelope in weight loss efficacy.",
                "category": "company",
                "datetime": 1784405100,
                "headline": "Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1"
              },
              {
                "id": 140944469,
                "url": "https://finnhub.io/api/news?id=b5473b5e218fa09a16b46b6e5c24f774f88167fed580755ba05200e7f3171e3c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170932409/image_2170932409.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Discover dividend stocks and REITs to hedge AI bubble risk, geopolitics, and inflation. Click for this survey of great income choices and my ultimate pick.",
                "category": "company",
                "datetime": 1784379799,
                "headline": "AI Bubble Risks Make Dividend Stocks Attractive Again"
              },
              {
                "id": 140940064,
                "url": "https://finnhub.io/api/news?id=ac87da50615f1f010650baf3bb0f355a4da8dee30fd79e6f816f432ace33de66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.",
                "category": "company",
                "datetime": 1784338500,
                "headline": "The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss"
              },
              {
                "id": 140944614,
                "url": "https://finnhub.io/api/news?id=307e412a7579741a0fddefc62643bfcb67d4a3ac5c44974b5af6ec260e2e65c5",
                "image": "https://image.cnbcfm.com/api/v1/image/108335808-1784189865798-gettyimages-168597290-000023514379_Unapproved.jpeg?v=1784189915&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.",
                "category": "company",
                "datetime": 1784336402,
                "headline": "Fat cat? Weight-loss drugs may be coming for your overweight pet"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140936300,
                "url": "https://finnhub.io/api/news?id=0619912c72d5845b90083140cf044c6cf4e0a8d961730467772681e825037883",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the",
                "category": "company",
                "datetime": 1784317490,
                "headline": "Sector Update: Healthcare Stocks Mixed Late Afternoon"
              },
              {
                "id": 140936218,
                "url": "https://finnhub.io/api/news?id=2c24fa0fdb2823735fb70b1842cf98957e158c30f0dfa40694d37dd6ddb56d04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is finally getting one up on its biggest rival.",
                "category": "company",
                "datetime": 1784314200,
                "headline": "Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win"
              },
              {
                "id": 140936302,
                "url": "https://finnhub.io/api/news?id=18a28194766e952b2004dfdc0dd7145a6e7447aafa867de1160f9d504358337e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Omada, an Eli Lilly partner, has soared more than 118% in just a few months, moving up the right side of a new base.",
                "category": "company",
                "datetime": 1784312238,
                "headline": "IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three Months"
              },
              {
                "id": 140934447,
                "url": "https://finnhub.io/api/news?id=0f8a98820b8480ee66afcccb43f385accf435545db7516d0820ed90496f03d0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.",
                "category": "company",
                "datetime": 1784307873,
                "headline": "Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal"
              },
              {
                "id": 140932951,
                "url": "https://finnhub.io/api/news?id=3d625afa6233dfda8012435905aba1d5df3aa390512caadad743af8838c21959",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL",
                "category": "company",
                "datetime": 1784303310,
                "headline": "Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says"
              },
              {
                "id": 140934448,
                "url": "https://finnhub.io/api/news?id=2db4e9cf90c0d1705ef9ac4634baeaab1cd71dde4d6eee17c8f6b2cdcd9d15d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.",
                "category": "company",
                "datetime": 1784302260,
                "headline": "Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout"
              },
              {
                "id": 140935407,
                "url": "https://finnhub.io/api/news?id=8826e67c12ece340942f8ddfe6e54dba131d04e0b4f590dec8e4fa46363ed686",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra",
                "category": "company",
                "datetime": 1784297052,
                "headline": "'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre"
              },
              {
                "id": 140934449,
                "url": "https://finnhub.io/api/news?id=49c1fc4d706d395e829dcca23b21cca2a2089f0bfeb708ce15ccc631200e73e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.",
                "category": "company",
                "datetime": 1784295000,
                "headline": "Prozac Maker Eli Lilly Just Bought a Psychedelics Company for $2.8 Billion — Here’s What It Could Mean for Mental Health"
              },
              {
                "id": 140936812,
                "url": "https://finnhub.io/api/news?id=ddb7b351f9f8705836d0230a60678ffe2dccb35e3ebcb9d758b026328760e71f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.",
                "category": "company",
                "datetime": 1784294312,
                "headline": "Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives"
              },
              {
                "id": 140931552,
                "url": "https://finnhub.io/api/news?id=c6c15f7b9be6e91a2b6a69a2ea6d788ce5a261368bcf8eac4d0da56c2623b497",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...",
                "category": "company",
                "datetime": 1784291820,
                "headline": "AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies"
              },
              {
                "id": 140931553,
                "url": "https://finnhub.io/api/news?id=2d514e51ba1de0bc99c88660e1ec2c4763504324cef780523cec5771378fb9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its position in Eli Lilly and Company, entered at approximately $350 per share in 2020, years before GLP-1 receptor agonists became the most consequential pharmaceutical story of the decade. Eli Lilly now trades above $1,200, a gain of more than 246% from the fund's e",
                "category": "company",
                "datetime": 1784291760,
                "headline": "Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200"
              },
              {
                "id": 140931094,
                "url": "https://finnhub.io/api/news?id=a099441d45540ba3c35e09bde3e7d5680b7c75d851fa7e59d58cb3e5bbe54317",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "High growth momentum investing combines stocks with accelerating earnings and sales with technical breakouts. Eli Lilly (LLY) scores 8/10 on growth metrics and 10/10 technically, showing strong EPS growth and a consolidation pattern near support.",
                "category": "company",
                "datetime": 1784291424,
                "headline": "Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup"
              },
              {
                "id": 140933581,
                "url": "https://finnhub.io/api/news?id=9a385d9550b1ee9b0a32e379b7afc16e0b87019409a9f9e52a697594be84c3b4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206372673/image_2206372673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "In this MoneyShow MoneyMasters Podcast episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the forces shaping the stock market - and the best profit opportunities for H2 2026.",
                "category": "company",
                "datetime": 1784291400,
                "headline": "Where To Invest Now In AI, Biotech, Small Caps, And Gold"
              },
              {
                "id": 140932383,
                "url": "https://finnhub.io/api/news?id=1f311ff4de315d7edf02a5775b38f1618c6853ffd33ba65344af3a27e9c15422",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2171515418/image_2171515418.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk is up 40% since April as oral Wegovy drives 2026 revenue upside, even vs. Eli Lilly. Click here to read this latest analysis of NVO stock.",
                "category": "company",
                "datetime": 1784286723,
                "headline": "Novo Nordisk: The Oral Wegovy Promise"
              },
              {
                "id": 140931554,
                "url": "https://finnhub.io/api/news?id=8e833337434d26111ded5c86258890a404cbdb9cb9562b348bdc437f86473f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Companies In The Article Are:ASTS,ATAI,LLY,USB,CFG",
                "category": "company",
                "datetime": 1784285940,
                "headline": "Company News for July 17, 2026"
              },
              {
                "id": 140930770,
                "url": "https://finnhub.io/api/news?id=a9cb5ef50d046f2090172e80e8d04609cceed9932ff390ad50fd6714924f060a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.",
                "category": "company",
                "datetime": 1784284758,
                "headline": "The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea"
              },
              {
                "id": 140930771,
                "url": "https://finnhub.io/api/news?id=836d5c7983976ad670e85b957aa146049f95f7a3a187820e94b0ce8fbfb763dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...",
                "category": "company",
                "datetime": 1784282890,
                "headline": "AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued"
              },
              {
                "id": 140930130,
                "url": "https://finnhub.io/api/news?id=3377160f9512a158105d6888c16a4984947f76362516a40b68a7a18e5253ab1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...",
                "category": "company",
                "datetime": 1784278860,
                "headline": "Eli Lilly's $3.8bn psychedelics bet is built on British science"
              },
              {
                "id": 140931555,
                "url": "https://finnhub.io/api/news?id=eea071582866f9a15bbd3fce4a5c994c426234c93c4ced9b24930135be030ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.",
                "category": "company",
                "datetime": 1784276667,
                "headline": "Compounders maintain a firm grip on the GLP-1 market"
              },
              {
                "id": 140934450,
                "url": "https://finnhub.io/api/news?id=d8e831dbde1b616936674d3f1873664b9939364f6123a996b22e4c9c5d69a664",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.",
                "category": "company",
                "datetime": 1784260860,
                "headline": "Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray"
              },
              {
                "id": 140928629,
                "url": "https://finnhub.io/api/news?id=072e3bfd616c4a91b32886e9b5950f43723730420d1b24eae7087362c56d8768",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.",
                "category": "company",
                "datetime": 1784257358,
                "headline": "Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today?"
              },
              {
                "id": 140928243,
                "url": "https://finnhub.io/api/news?id=2f31ba932cf8c2ef816103d96af4705fe4ad4419fb7e0cbbf96e09fde5582eb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]",
                "category": "company",
                "datetime": 1784247565,
                "headline": "AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly"
              },
              {
                "id": 140927325,
                "url": "https://finnhub.io/api/news?id=301fe28c4328fa8aefc664e07a0dc4705d04a534df1d54ea88fc3cfc6ca48ccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The psychedelic drugmaker is being acquired.",
                "category": "company",
                "datetime": 1784241122,
                "headline": "Why AtaiBeckley Stock Soared Today"
              },
              {
                "id": 140927361,
                "url": "https://finnhub.io/api/news?id=f0ad3d9abaaef5ea1ab7af0402f99bf8fd9114bfa921579e54c90ed1027ccc23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan all raised their price targets in the first half of the month. Then UBSwent higher than nearly all of them. UBS's call is worth watching closely because ...",
                "category": "company",
                "datetime": 1784240220,
                "headline": "UBS strongly resets Lilly stock target"
              },
              {
                "id": 140926080,
                "url": "https://finnhub.io/api/news?id=cb5c1dbdcf55a9a6cafff94dede8cd51aa88b20f29756e937b5a3a53fbbd37f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.",
                "category": "company",
                "datetime": 1784236745,
                "headline": "Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140927352,
                "url": "https://finnhub.io/api/news?id=4167742add66fef57c25a1a3ec1f1df12211a8746213a22c8fcf36bdd9e9a214",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.",
                "category": "company",
                "datetime": 1784232612,
                "headline": "Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today"
              },
              {
                "id": 140924321,
                "url": "https://finnhub.io/api/news?id=119450ead9605d895871452ae06130087451765f430cd380ee5fd7b703906adf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Acquisition could strengthen its neuroscience growth strategy",
                "category": "company",
                "datetime": 1784229240,
                "headline": "Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal"
              },
              {
                "id": 140924322,
                "url": "https://finnhub.io/api/news?id=f6832ec569d0a664d884d1a33a1d3f3c524bb48490c7102b57a8d102368970dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Lilly a late-stage psychedelic treatment for hard-to-treat depression.",
                "category": "company",
                "datetime": 1784228901,
                "headline": "Eli Lilly Buys AtaiBeckley for Up to $3.8 Billion"
              },
              {
                "id": 140924323,
                "url": "https://finnhub.io/api/news?id=17b5608d3f51824e6f9d24c6fa92f62b09becd541a01e49b7ac840853f496844",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly will pay $6.75 a share in cash, plus up to $1 billion in milestones",
                "category": "company",
                "datetime": 1784228342,
                "headline": "AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout"
              },
              {
                "id": 140924324,
                "url": "https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.",
                "category": "company",
                "datetime": 1784224421,
                "headline": "Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"
              },
              {
                "id": 140922620,
                "url": "https://finnhub.io/api/news?id=506a6d3987e001711e5073c22c88fb4144ff5020dcf521a69fb211198508d96b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) could see further momentum from positive amylin and tirzepatide data supporting its",
                "category": "company",
                "datetime": 1784222977,
                "headline": "Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says"
              },
              {
                "id": 140934029,
                "url": "https://finnhub.io/api/news?id=6d471199f096114656b56d4275e818cfbb2bc50be65cc8dedd009692dea7490f",
                "image": "https://image.cnbcfm.com/api/v1/image/108336287-17842371321784237129-47205829193-1080pnbcnews.jpg?v=1784237131&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles joins 'Fast Money' to talk Eli Lilly investing in psychedelics.",
                "category": "company",
                "datetime": 1784222964,
                "headline": "Eli Lilly makes deal to buy psychedelics maker"
              },
              {
                "id": 140927363,
                "url": "https://finnhub.io/api/news?id=534d1a6b42c0334dbf8cafc3cad3ddeee016e95277c1851ed1e29c9c58f68b74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.",
                "category": "company",
                "datetime": 1784221847,
                "headline": "Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock"
              },
              {
                "id": 140934030,
                "url": "https://finnhub.io/api/news?id=4903171e17fb6e4bd355548bf865a7e1b4384a2630a8b581fff88ec10d9ab417",
                "image": "https://image.cnbcfm.com/api/v1/image/108336270-17842356001784235597-47205439738-1080pnbcnews.jpg?v=1784235599&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "UBS Michael Yee joins 'Closing Bell Overtime' to talk what could be ahead for M&A in the biotech space.",
                "category": "company",
                "datetime": 1784221679,
                "headline": "UBS Michael Yee talks biotech M&A outlook"
              },
              {
                "id": 140924325,
                "url": "https://finnhub.io/api/news?id=5cac8aeaadc80d5c961ac173e6177a0270891a7bded5d214f7cce61c7d5a7c54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.",
                "category": "company",
                "datetime": 1784220900,
                "headline": "NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920957,
                "url": "https://finnhub.io/api/news?id=2351160fc5075468e912fbaf74b5cfd23993b1dab4ff9e8a095cb195c5375131",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.",
                "category": "company",
                "datetime": 1784215684,
                "headline": "Novo secures European approval for oral Wegovy to extend lead over Lilly"
              },
              {
                "id": 140920958,
                "url": "https://finnhub.io/api/news?id=9372875bc22c8d5be7b62ecdcd9c746c22eaad70edafc58e140ef5d483a1c10e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly tripped into the psychedelics space Thursday with the up-to-$3.8 billion acquisition of AtaiBeckley.",
                "category": "company",
                "datetime": 1784215422,
                "headline": "Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover"
              },
              {
                "id": 140920959,
                "url": "https://finnhub.io/api/news?id=5ca65886125060506cbb858303589dfe9feb9b4c15f873a6449871aa096ae0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.",
                "category": "company",
                "datetime": 1784213040,
                "headline": "Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?"
              },
              {
                "id": 140920960,
                "url": "https://finnhub.io/api/news?id=dcb13dfe6397af2cbeaa74c64c0e9be36e47df6f995767a9a47b4d981caa671c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to a",
                "category": "company",
                "datetime": 1784212910,
                "headline": "Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline"
              },
              {
                "id": 140920961,
                "url": "https://finnhub.io/api/news?id=7c51533644ebaccb800577df079ea936536f8854a591482b9c7d88d8913b2420",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.",
                "category": "company",
                "datetime": 1784212487,
                "headline": "Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover"
              },
              {
                "id": 140923194,
                "url": "https://finnhub.io/api/news?id=3bfcec2845747bfa84db81187b47f21349674f00539e018d4eb899f75da08e0b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283213489/image_2283213489.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline outlook. Click to read more.",
                "category": "company",
                "datetime": 1784211699,
                "headline": "AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline"
              },
              {
                "id": 140922932,
                "url": "https://finnhub.io/api/news?id=f3a4d2c7b17cefc1fe8780374c5ea4235b62e340ae9b8ef94162127e830a8ee3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2246468119/image_2246468119.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly and Company’s $3.8bn AtaiBeckley deal targets psychedelic mental health drugs, using GLP-1 cash to expand. Click for a look at LLY and ATAI stocks.",
                "category": "company",
                "datetime": 1784210838,
                "headline": "Eli Lilly Acquires Psychedelics Specialist AtaiBeckley - What Investors Should Know"
              },
              {
                "id": 140920962,
                "url": "https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.",
                "category": "company",
                "datetime": 1784210761,
                "headline": "Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140920963,
                "url": "https://finnhub.io/api/news?id=c541a1270983bbfadf649c1e470b8de10d589441056b228134941f27c4d04128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.",
                "category": "company",
                "datetime": 1784210100,
                "headline": "ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919684,
                "url": "https://finnhub.io/api/news?id=3c1d0c5d538a743bfd742623f0acc2aef62a674f35f910705872ef3bb868b52a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly announced it is buying AtaiBeckley in a bet on neuroscience and psychiatric pharmaceuticals.",
                "category": "company",
                "datetime": 1784208204,
                "headline": "Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919687,
                "url": "https://finnhub.io/api/news?id=5df8c72991843888b0d0f3e05373e17ba374ae472704587f3c93dd3f1211506c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression...",
                "category": "company",
                "datetime": 1784205660,
                "headline": "AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion"
              },
              {
                "id": 140923161,
                "url": "https://finnhub.io/api/news?id=7717e8276d3ecf294779e1a9f6751a3055a6f5d9930c10cb23545b1fb4b77d34",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Depression-research-with-Magic-Mushrooms.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.",
                "category": "company",
                "datetime": 1784205378,
                "headline": "Why Is GH Research Stock Trading Higher on Thursday?"
              },
              {
                "id": 140923185,
                "url": "https://finnhub.io/api/news?id=2e178b8f0183c94552d1467239c3cd5546253744889021898e0045612cc8d0c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Agitated-Depression-Mentioned.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.",
                "category": "company",
                "datetime": 1784205353,
                "headline": "AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal"
              },
              {
                "id": 140919688,
                "url": "https://finnhub.io/api/news?id=728ccf30fd24b99d2fc7994bdcb1c1b7b9149886f20bd71f8122f987d018edec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Psychedelic drugmaker  AtaiBeckley  was surging 34% ahead of the open Thursday after pharma giant  Eli Lilly  agreed a deal to buy the company.  AtaiBeckley shares were up 34.2% to $7.19 in premarket trading after the deal was confirmed.  Lilly will acquire AtaiBeckley for $6.75 per share in cash, plus up to $2.50 per share upon reaching certain developmental and regulatory milestones, the companies said in a press release.",
                "category": "company",
                "datetime": 1784205300,
                "headline": "AtaiBeckley Stock Is Soaring 34% as Eli Lilly Agrees to Buy Psychedelic Drugmaker"
              },
              {
                "id": 140922621,
                "url": "https://finnhub.io/api/news?id=acd6c4070d3b959de48eb3b93938602a11a6d376c65fde7307eafdb6227f04e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.",
                "category": "company",
                "datetime": 1784204340,
                "headline": "Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics"
              },
              {
                "id": 140920920,
                "url": "https://finnhub.io/api/news?id=19bf65b45f39954e551257debea7ac82f53fa593583892062a74d662bf2a32d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Oil prices traded just below $80 a barrel, despite further escalation in the Middle East",
                "category": "company",
                "datetime": 1784203260,
                "headline": "Nasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risers"
              },
              {
                "id": 140919689,
                "url": "https://finnhub.io/api/news?id=0f4a56954429321eb46d94fab50f3184e620d6470ba0f7d0ac67f06b2cdc260c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.",
                "category": "company",
                "datetime": 1784203229,
                "headline": "The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?"
              },
              {
                "id": 140919690,
                "url": "https://finnhub.io/api/news?id=872dcdb1b794074e3c3b47d33c5b3c438dabc0540094151f4bc85d87bd2f0ffe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Kalshi Will Offer Sports-Style Betting on Drug Trial Results"
              },
              {
                "id": 140918818,
                "url": "https://finnhub.io/api/news?id=94cb59081a3cdc58b091e730c10afc5484d4a52ea3effceaf65f9adcc274f133",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.",
                "category": "company",
                "datetime": 1784202291,
                "headline": "Why Psychedelic stocks are surging today"
              },
              {
                "id": 140919691,
                "url": "https://finnhub.io/api/news?id=59934cad70f3745b16c56da035f9c0e9002d0712d52cd31505215670afb1098e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.",
                "category": "company",
                "datetime": 1784202165,
                "headline": "ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?"
              },
              {
                "id": 140919692,
                "url": "https://finnhub.io/api/news?id=625206521bb4122c1ac2b7cded2161b9bf732e2f6a52e5b991e1c4a1386ea320",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.",
                "category": "company",
                "datetime": 1784202060,
                "headline": "Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion"
              },
              {
                "id": 140923186,
                "url": "https://finnhub.io/api/news?id=9fadc90c7b0f8fe8655d1d5482c0333b483cc9faa8b92ce60d0562c29fee2e65",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/16-7-2026-105158-thebambooworks-com.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals\n\n\n\n\n\n\n\nimage credit: Bamboo Works\n\n\n\nKey",
                "category": "company",
                "datetime": 1784200998,
                "headline": "World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships"
              },
              {
                "id": 140918819,
                "url": "https://finnhub.io/api/news?id=5828136d0cf4723b248a203413fc988988a3f0c4636af496a69298f9b735370b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation",
                "category": "company",
                "datetime": 1784200206,
                "headline": "Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion"
              },
              {
                "id": 140918820,
                "url": "https://finnhub.io/api/news?id=9ab32d97c646ba6ba69f92cf9f537853dcb1792d95d7e02b06dad4afda3ffc33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The radiopharma specialist will use earnings from this mega-round to progress ADVC001 and build manufacturing infrastructure to prepare for potential commercialisation.",
                "category": "company",
                "datetime": 1784199406,
                "headline": "Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III"
              },
              {
                "id": 140918821,
                "url": "https://finnhub.io/api/news?id=5b6ef3fb818440d1f94b2bdd6cc8cc2f68886b4120f8b122e133b9047f4d3c16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions"
              },
              {
                "id": 140918822,
                "url": "https://finnhub.io/api/news?id=11d0a6004abbc4f60986875de99d32415a01e49ccc22148cf31e5129be302058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha",
                "category": "company",
                "datetime": 1784198031,
                "headline": "GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)"
              },
              {
                "id": 140918823,
                "url": "https://finnhub.io/api/news?id=1d80b9a8d2ddd5cb96f08d8666a8551f85b05b8f0a688e6dbe05ec14246372fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AtaiBeckley (NASDAQ:ATAI) shares jumped as much as 53% in premarket trading on Thursday after reports emerged that Eli Lilly (NYSE:LLY) is in discussions to acquire the psychedelic drug developer. Potential deal would broaden Lilly’s neuroscience portfolioAccording to BMO Capital Markets analyst Evan David Seigerman, an acquisition of AtaiBeckley would strengthen Eli Lilly’s presence in psychiatry while supporting its strategy of expanding beyond its established cardiometabolic business.",
                "category": "company",
                "datetime": 1784197852,
                "headline": "AtaiBeckley shares soar on reports of potential Eli Lilly takeover talks (ATAI)"
              },
              {
                "id": 140918824,
                "url": "https://finnhub.io/api/news?id=52867159ae7fa109db891021a556aec1c3c48625b31192263dc38364bafc2194",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Psychedelic drugmaker  AtaiBeckley  was surging 50% ahead of the open Thursday following a report that pharma giant  Eli Lilly  is nearing a deal to buy the company .  A deal, being negotiated at a premium, could be announced as early as this week, Bloomberg reported, citing people familiar with the matter.  The shares jumped 22% in a single day in April when President Donald Trump signed a directive to accelerate the Food and Drug Administration’s review of psychedelic drugs for serious mental illnesses.",
                "category": "company",
                "datetime": 1784194560,
                "headline": "This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks"
              },
              {
                "id": 140920374,
                "url": "https://finnhub.io/api/news?id=2d2f2d5b4ce3da3d4f480a303cd89cd505bb3ee9abc505cec2f253e909b24ab3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Wall-Street-New-York-Stock-Exchange.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "U.S. stock futures declined on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices fell, following Wednesday's higher close.",
                "category": "company",
                "datetime": 1784194134,
                "headline": "Stock Market Today: Dow Futures Rise, S&P 500 Falls As Trump Says Iran Wants To Negotiate— AtaiBeckley, J B Hunt, AST SpaceMobile in Focus (UPDATED)"
              },
              {
                "id": 140923188,
                "url": "https://finnhub.io/api/news?id=d85d188ac31f0be7b67de702da053ebe6f33ee097b1395995d39e56ab6610ae9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/GLP-1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you",
                "category": "company",
                "datetime": 1784193389,
                "headline": "Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027"
              },
              {
                "id": 140920423,
                "url": "https://finnhub.io/api/news?id=763f11df05c29ccbe7aa8e52eef03dc88147aed9e0448dcd28f80bcc2f6fc924",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Experts-Warn-On-Costly-Attacks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.",
                "category": "company",
                "datetime": 1784191992,
                "headline": "Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’"
              },
              {
                "id": 140918113,
                "url": "https://finnhub.io/api/news?id=7c0a4067213f0ac9dd79c30092bae763a6ffc4ab1541ce2be543007335604983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Faced with the dual pressures of shifting consumer habits and emerging health trends, General Mills finds itself in a challenging market position.",
                "category": "company",
                "datetime": 1784188800,
                "headline": "Bear of the Day: General Mills (GIS)"
              },
              {
                "id": 140922147,
                "url": "https://finnhub.io/api/news?id=b91056a9332422e00ac8017cd0fa3160333dd105d6e7743970ef0634fcd4b5c3",
                "image": "https://image.cnbcfm.com/api/v1/image/107387028-1710350423351-gettyimages-1543156724-AFP_33PH3NQ.jpeg?v=1769095576&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1784187631,
                "headline": "Stocks making the biggest moves premarket: UnitedHealth, TSMC, GE Aerospace, J.B. Hunt & more"
              },
              {
                "id": 140922148,
                "url": "https://finnhub.io/api/news?id=4c83505cb55e39a788e69d9c3fb67029d5d170d1e07d86a9410cc2a237477d2a",
                "image": "https://image.cnbcfm.com/api/v1/image/108335869-17842002661784200239-47196619443-1080pnbcnews.jpg?v=1784200265&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles reports on the latest news on Eli Lilly.",
                "category": "company",
                "datetime": 1784187404,
                "headline": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion"
              },
              {
                "id": 140920376,
                "url": "https://finnhub.io/api/news?id=2a1ed56ceb68df1555e5665a012a2d69ddef0ef3e940852bb1e13d3c617a22e2",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) and AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for",
                "category": "company",
                "datetime": 1784184547,
                "headline": "Lilly To Acquire AtaiBeckley For $6.75 Per Share In Cash Plus Up To $2.50 Per Share In A Contingent Value Right Dependent Upon Milestones Related To The BPL-003 And VLS-01 Programs; Deal Valued At Up To ~$3.8B"
              },
              {
                "id": 140922149,
                "url": "https://finnhub.io/api/news?id=2480804da292e0ead07986655647a4d2a0d1deccf247abc5c72a5653a705b414",
                "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1779898152&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.",
                "category": "company",
                "datetime": 1784184353,
                "headline": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction"
              },
              {
                "id": 140920377,
                "url": "https://finnhub.io/api/news?id=a942ecb90b901feab023b2ff6db25f65861613b0b17a9d50cfd879cd158c2ef7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Front-Royal--Usa---May-27--2021-Highway-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA, and CMPS.",
                "category": "company",
                "datetime": 1784175957,
                "headline": "Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket"
              },
              {
                "id": 140916521,
                "url": "https://finnhub.io/api/news?id=d529e6a023f7f79ba8d0d30207d052ee94ecba263e105a296569f7c382859733",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "VC Magnus Sigurdsson said a rival bidder is unlikely after AtaiBeckley’s months-long structured sale process.",
                "category": "company",
                "datetime": 1784172028,
                "headline": "ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly"
              },
              {
                "id": 140920378,
                "url": "https://finnhub.io/api/news?id=8498456d06ddd2181634279c4582435ab0fa1ce31fad449167b8f09371e24f03",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Trading-Investment-Charts--Investment-Fi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.",
                "category": "company",
                "datetime": 1784161760,
                "headline": "AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED)"
              },
              {
                "id": 140916099,
                "url": "https://finnhub.io/api/news?id=27351ac7c79e321f77c750732adfb94ac1b629a887f19f9711abdd32dcf0e1db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is nearing an agreement involving AtaiBeckley, Bloomberg reported on Wednesday, citing people familiar with the matter.",
                "category": "company",
                "datetime": 1784158764,
                "headline": "Why Is ATAI Stock Soaring 59% After-Hours?"
              },
              {
                "id": 140914216,
                "url": "https://finnhub.io/api/news?id=b390ec668e38345dfeef3aff61fea4ff4198e1ed8c7c64c0564ef47c2491661b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wegovy Pill Wins Big as Eli Lilly Rollout Lags",
                "category": "company",
                "datetime": 1784145879,
                "headline": "Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions"
              },
              {
                "id": 140914217,
                "url": "https://finnhub.io/api/news?id=728eeda0f5cd114e57b2b33bdc9915750ee8c98f90d45e2c1a27ee97e48db7c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wegovy captured about 89% of weekly prescriptions.",
                "category": "company",
                "datetime": 1784145757,
                "headline": "Lilly's Obesity Pill Trails Wegovy"
              },
              {
                "id": 140912796,
                "url": "https://finnhub.io/api/news?id=5ccc34e4756d7738080b340739486447e99093318707e151a7d32d918ec99aee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the",
                "category": "company",
                "datetime": 1784144857,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140911279,
                "url": "https://finnhub.io/api/news?id=0ca1c1856667dd70b66b3f69a7a38572ad4af4d10dff044da49f8c9d3c91e9d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Oral Wegovy is now cleared in all EU member states.",
                "category": "company",
                "datetime": 1784137749,
                "headline": "NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart"
              },
              {
                "id": 140911280,
                "url": "https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State",
                "category": "company",
                "datetime": 1784137282,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140911281,
                "url": "https://finnhub.io/api/news?id=94f35e15deebced35b04ff5c406ec8d6fd1ae0f0aa49c08462683383ce3c0bbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.",
                "category": "company",
                "datetime": 1784131620,
                "headline": "RHHBY's Gazyva Gets FDA Priority Review for Label Expansion"
              },
              {
                "id": 140909556,
                "url": "https://finnhub.io/api/news?id=078bec1491fb0d2386bee78b68cb24d0e112102bf4d9c5e65ba67d4356afdbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.",
                "category": "company",
                "datetime": 1784127060,
                "headline": "Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data"
              },
              {
                "id": 140909557,
                "url": "https://finnhub.io/api/news?id=87c4cf90385ae76ab651add642a65e43416c03a34848a9841d154421a6af5dee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.",
                "category": "company",
                "datetime": 1784126810,
                "headline": "VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth"
              },
              {
                "id": 139941219,
                "url": "https://finnhub.io/api/news?id=f5af666d096d8f45d34d78bac257ee6d0c8030a696cc155fe2fc4bece3190a60",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1784120481,
                "headline": "Shares of several banks and financial services companies are trading higher amid overall market strength as investors anticipate this week's Fed Reserve meeting."
              },
              {
                "id": 140910531,
                "url": "https://finnhub.io/api/news?id=57000288ae8e34864fe003c9dc01032ef3345e614ac1f58d27e5e9465af2590c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365641802/image_1365641802.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "AstraZeneca PLC Q2 2026 preview: revenue growth, Enhertu sales surge and EU approval, plus risk/reward after Wainua trial setback. Click for this AZN stock update.",
                "category": "company",
                "datetime": 1784120082,
                "headline": "AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback"
              },
              {
                "id": 140908136,
                "url": "https://finnhub.io/api/news?id=12e41338336f8c67eec77e854a143b296e63e02f393b5d4a57bc364fdfcd58eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Management jacked up its forecast in a way that's impossible to ignore, and while the stock has already ripped higher, the real debate is whether this is a new reality or a temporary sugar high.",
                "category": "company",
                "datetime": 1784119913,
                "headline": "Dell Stock Lit The Afterburners. Is There Enough Fuel For The Trip?"
              },
              {
                "id": 140911087,
                "url": "https://finnhub.io/api/news?id=e3877bf217cf9a3696a761c9f102d1877ba97d809c56c59d19aaa77754edfc0f",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.",
                "category": "company",
                "datetime": 1784118629,
                "headline": "If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140908240,
                "url": "https://finnhub.io/api/news?id=d3b6e5cb1540fdc9d39a278ae116d1281f06fc87e1f679128bae0211484e8823",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly. In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received $5 million as a m",
                "category": "company",
                "datetime": 1784117100,
                "headline": "VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027"
              },
              {
                "id": 140911088,
                "url": "https://finnhub.io/api/news?id=b866d74ab0401557f0cf0728da580412a4e7b405ecbfc9c7ec38f00fcbfedc37",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1500 to $1600.",
                "category": "company",
                "datetime": 1784114487,
                "headline": "Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $1600"
              },
              {
                "id": 140911089,
                "url": "https://finnhub.io/api/news?id=e27f979971abd25781adf4005863bf7dcc2291c17f7ae62c49370ce68f219b6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Hands--Slide-And-Science-Closeup-For-Mic.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.",
                "category": "company",
                "datetime": 1784114424,
                "headline": "Why Vivosim Labs Shares Are Rocketing on Wednesday?"
              },
              {
                "id": 140907418,
                "url": "https://finnhub.io/api/news?id=19a91e27c907e4d474ed5f920d99f42f152b62d573c112f68960964509e02e31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M",
                "category": "company",
                "datetime": 1784109600,
                "headline": "Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million"
              },
              {
                "id": 140911090,
                "url": "https://finnhub.io/api/news?id=f5cdcf87fd1a86ae3ecd1079b8e91ebecce0876162b6b4c797c84134488a8d83",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue",
                "category": "company",
                "datetime": 1784102947,
                "headline": "VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly"
              },
              {
                "id": 140905696,
                "url": "https://finnhub.io/api/news?id=9acdd92ee551cbdda90c829dc3d0bd2375681e45cc8361c5fd49c1f910a68c42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...",
                "category": "company",
                "datetime": 1784092274,
                "headline": "Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In Broader Cancers"
              },
              {
                "id": 140904204,
                "url": "https://finnhub.io/api/news?id=d355869fae15f49968e962d9308dd96b767ce8afecabeef0d4860a8b611ae233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.",
                "category": "company",
                "datetime": 1784065506,
                "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140901437,
                "url": "https://finnhub.io/api/news?id=85a7dde379b55c28caed39928be7f2f662379741b95f70f30eb6804a9b58aabe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin",
                "category": "company",
                "datetime": 1784056545,
                "headline": "Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors"
              },
              {
                "id": 140901438,
                "url": "https://finnhub.io/api/news?id=9fd95fbb80f47cce96cfbcae493bee66c1a8f0e6fab86029428940d7057e1de6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The presentation on  Biogen’s  experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects.  Instead, Biogen stock is down 6%, to $197.  Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.",
                "category": "company",
                "datetime": 1784052540,
                "headline": "Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140899731,
                "url": "https://finnhub.io/api/news?id=ab9efa283f15df1648247f3f9e34e0ef7c686344770d8bd769c997f910e901a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.",
                "category": "company",
                "datetime": 1784045640,
                "headline": "Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi"
              },
              {
                "id": 140899690,
                "url": "https://finnhub.io/api/news?id=9e7ebc357240455e6e55a9a903db00b21fce46bf6f2101bbe4e9afbcf279c728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While the company's AI spending commands attention, the real story is how the technology is already accelerating the core business that funds it all.",
                "category": "company",
                "datetime": 1784045347,
                "headline": "What Could Power The Next Rally In META Stock"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140903881,
                "url": "https://finnhub.io/api/news?id=4a193f2e0488f271f259a27b32b77b0cd93c67049404d489714065015d5de8a8",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive",
                "category": "company",
                "datetime": 1784038889,
                "headline": "FDA Grants Approval For Eli Lilly's Selpercatinib For Patients With Locally Advanced Or Metastatic Solid Tumors With A RET Gene Fusion"
              },
              {
                "id": 140898041,
                "url": "https://finnhub.io/api/news?id=f81b5704db160b35b4aa4e9fe38b791120b54b59fe0684be4ae1b6f05f59f94e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.",
                "category": "company",
                "datetime": 1784037240,
                "headline": "Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge"
              },
              {
                "id": 140896832,
                "url": "https://finnhub.io/api/news?id=cd7d8f48709f03cfb02a2c4fe33cae2ce945561754784b3a831991e3b9c5278f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN FRANCISCO, July 14, 2026--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.",
                "category": "company",
                "datetime": 1784034000,
                "headline": "Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design"
              },
              {
                "id": 140903882,
                "url": "https://finnhub.io/api/news?id=c81b00d47be8eecf014e65f40cae832c952d731b362ed2dcb0222dccca3c8ab9",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bernstein  analyst Courtney Breen   maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1300 to $1385.",
                "category": "company",
                "datetime": 1784025542,
                "headline": "Bernstein Maintains Outperform on Eli Lilly, Raises Price Target to $1385"
              },
              {
                "id": 140895900,
                "url": "https://finnhub.io/api/news?id=c957d7aab767bbff736dd78fe1f3c966b7b1792093d60a3ffc342b4647afabbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eyes are on the rollout of Lilly's new weight loss pill.",
                "category": "company",
                "datetime": 1784025000,
                "headline": "Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?"
              },
              {
                "id": 140895218,
                "url": "https://finnhub.io/api/news?id=ac09b1e825d85078efac14d5865d13b080a0223865d4193158494544f04990de",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Louis Navellier’s eight-rule growth investing framework identifies stocks with strong earnings momentum and efficiency. Eli Lilly (LLY) passes this screen, showing exceptional sales, earnings, and cash flow growth.",
                "category": "company",
                "datetime": 1784022636,
                "headline": "Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum"
              },
              {
                "id": 140893297,
                "url": "https://finnhub.io/api/news?id=7dfb55981816cba5173c9bfa6229bb73be2048d1ec30f80b16845c2bb2712d95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra.",
                "category": "company",
                "datetime": 1783986466,
                "headline": "MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug"
              },
              {
                "id": 140889976,
                "url": "https://finnhub.io/api/news?id=853634e3215adae0307c8aa5ba126a884c266f5f82638bd677c0b4bb959be1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.",
                "category": "company",
                "datetime": 1783965635,
                "headline": "Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher"
              },
              {
                "id": 140888353,
                "url": "https://finnhub.io/api/news?id=4485315c448a89a6ae42a93ee1eff88cb436b1981d6da3cd995a10471ecdc57d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts",
                "category": "company",
                "datetime": 1783961547,
                "headline": "Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group"
              },
              {
                "id": 140890428,
                "url": "https://finnhub.io/api/news?id=19d739b4927a93cabbd2b4851d7ce4d2fd6f440ccf87508ea6d90be82d6ca59d",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://fingfx.thomsonreuters.com/gfx/legaldocs/jnpwzaojlvw/TEVA%20LILLY%20FORTEO%20LAWSUIT%207thcir.pdf",
                "category": "company",
                "datetime": 1783956607,
                "headline": "U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement"
              },
              {
                "id": 140886796,
                "url": "https://finnhub.io/api/news?id=f9b778750087e7257dcaa89a698cc3abdd980ec775cf51eb75bfbabbca689d65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.",
                "category": "company",
                "datetime": 1783954101,
                "headline": "Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week"
              },
              {
                "id": 140892268,
                "url": "https://finnhub.io/api/news?id=8888a5803a2f00d091ba116f4ce07d087b72c3d912194a3c45b48d32214a6c29",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "UBS  analyst Michael Yee   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1250 to $1425.",
                "category": "company",
                "datetime": 1783952743,
                "headline": "UBS Maintains Buy on Eli Lilly, Raises Price Target to $1425"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140884976,
                "url": "https://finnhub.io/api/news?id=528f6379fc7107f3ed28cd97001d1af154a02757ac72e99736c901f4f9a86c42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RICHMOND, Va., July 13, 2026--Capital Square, a leading sponsor of tax-advantaged real estate investments and a national developer and manager of housing communities, has fully subscribed CS1031 Richmond Active Living Apartments, DST, a Regulation D private placement offering that raised equity from 108 investors. The Delaware statutory trust holds a 165-unit, Class A, age-restricted multifamily community in the Short Pump suburb of Richmond, Virginia, near Capital Square’s headquarters.",
                "category": "company",
                "datetime": 1783940400,
                "headline": "Capital Square Fully Subscribes Richmond Active-Adult DST Offering"
              },
              {
                "id": 140892269,
                "url": "https://finnhub.io/api/news?id=67a50f94bc36f1f379bdaa11c0218a66643ef22ad54a7b101d03828308b2f40d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Eli-Lilly-Tax-Payments-Shift.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.",
                "category": "company",
                "datetime": 1783932562,
                "headline": "Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades"
              },
              {
                "id": 140884344,
                "url": "https://finnhub.io/api/news?id=4ceb91cd7becada7604bb3488ec60c7e743439b05e47c16231893ddc48558cbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.",
                "category": "company",
                "datetime": 1783932180,
                "headline": "Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors"
              },
              {
                "id": 140892270,
                "url": "https://finnhub.io/api/news?id=5d503b25613f831bbf329175c1021d4821c28b0e8c30717ea3fc6eb9cea5d2fb",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Guggenheim  analyst Seamus Fernandez   maintains Eli Lilly (NYSE:LLY) with a Buy and lowers the price target from $1235 to $1273.",
                "category": "company",
                "datetime": 1783931868,
                "headline": "Guggenheim Maintains Buy on Eli Lilly, Lowers Price Target to $1273"
              },
              {
                "id": 140883830,
                "url": "https://finnhub.io/api/news?id=10a857ac60fefead3fd586415331027da653fab64eb60679569e05a388e39fde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PARIS, July 13, 2026--Sofinnova Partners (\"Sofinnova\"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financi",
                "category": "company",
                "datetime": 1783922400,
                "headline": "Sofinnova Partners Appoints David Evans as Partner"
              },
              {
                "id": 140887884,
                "url": "https://finnhub.io/api/news?id=d6b97e5e2d0a0da4424ed28339ad0a3425ddba2d38f6891101f093022cabcc9c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Closeup-one-hundred-US-dollar-bills-unde.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "HHS watchdog projected $5.56 billion in recoveries and savings over six months despite enforcement falling to a two-year low.",
                "category": "company",
                "datetime": 1783912149,
                "headline": "Federal Health Watchdog Projects $5.56 Billion in Recoveries and Savings, Despite Enforcement Hitting Two-Year Low"
              },
              {
                "id": 140871121,
                "url": "https://finnhub.io/api/news?id=5f2a2d16390b18a79e25fba4b67df2bdfcba26a350c96041ac7d34fa5a5f21ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.",
                "category": "company",
                "datetime": 1783776900,
                "headline": "3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026"
              },
              {
                "id": 140869911,
                "url": "https://finnhub.io/api/news?id=bcd8f15ebb03e3568bc541bfac55c5852ab3cd576eba6ef9d27eee8464f7e20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There are good reasons to invest in Lilly and to hold off.",
                "category": "company",
                "datetime": 1783760640,
                "headline": "Should You Buy Eli Lilly Stock? Here's My Honest Take."
              },
              {
                "id": 140868785,
                "url": "https://finnhub.io/api/news?id=1222dbd0e33abeb26678833c523058c9f542d2588c9d968ce5c8336f051c40b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly plans to present new Alzheimer's research at the 2026 Alzheimer's Association International Conference, including long term data on Kisunla (donanemab-azbt). The company will share updated safety and biomarker findings from its Kisunla program. Eli Lilly will also outline progress on blood based P-tau217 diagnostics that could support broader Alzheimer's screening. Eli Lilly, traded as NYSE:LLY, is set to bring fresh Alzheimer's data to the forefront, while attention has recently...",
                "category": "company",
                "datetime": 1783743328,
                "headline": "Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC"
              },
              {
                "id": 140868961,
                "url": "https://finnhub.io/api/news?id=7c6dcedf16148bc616a2adf5030c7ad17be73914ef7a21ec565cd80def4de433",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351962969/image_1351962969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The “sell AI” trade that started in early summer has quietly grown a positive side, and that side is healthcare.",
                "category": "company",
                "datetime": 1783736700,
                "headline": "Macro Note: The Tech Unwind Grew A Second Leg, And It's Healthcare"
              },
              {
                "id": 140866922,
                "url": "https://finnhub.io/api/news?id=25d7acb47f3ed9eca0886a9f0080884afee31f93b3c3913488146df9acb10ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.",
                "category": "company",
                "datetime": 1783726500,
                "headline": "Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?"
              },
              {
                "id": 140864232,
                "url": "https://finnhub.io/api/news?id=91a02918a5278124662a610b3899e8198d2c7971f595e01efcfbf99480df0d7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.",
                "category": "company",
                "datetime": 1783699478,
                "headline": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout"
              },
              {
                "id": 140862896,
                "url": "https://finnhub.io/api/news?id=0c301d7f2b398dc00ad7c779c5814ef6ecc68d67de60e9199a241944cb2c21bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.",
                "category": "company",
                "datetime": 1783692660,
                "headline": "NVO Rallies 11% in a Month: How Should Investors Play the Stock?"
              },
              {
                "id": 140866545,
                "url": "https://finnhub.io/api/news?id=9cc45cae68dafe8692fc093002acadbb7de1fd69729bca9b60e6ed9154568cb3",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "B of A Securities  analyst Jason Gerberry   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1251 to $1334.",
                "category": "company",
                "datetime": 1783692345,
                "headline": "B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334"
              },
              {
                "id": 140864871,
                "url": "https://finnhub.io/api/news?id=0b230cf4ef13909094f0c290b905986804d9f285937fd22e25e8cdfb17957867",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783690507,
                "headline": "6 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140860646,
                "url": "https://finnhub.io/api/news?id=a5275756f88fc3a60e681d21dbc3afb05ca02eb4d3c2800251dc78113098a910",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the latest monthly list of new buys by the best mutual funds, top money managers aggressively scooped up shares of 19 stocks, including Eli Lilly, GE Aerospace, Taiwan Semiconductor Manufacturing and CrowdStrike.",
                "category": "company",
                "datetime": 1783682566,
                "headline": "Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five"
              },
              {
                "id": 140859133,
                "url": "https://finnhub.io/api/news?id=f3b3f970a75ff80e094b724eb87270ab4f26b82709f3ffaea915396f145b4708",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.",
                "category": "company",
                "datetime": 1783665420,
                "headline": "Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN"
              },
              {
                "id": 140855712,
                "url": "https://finnhub.io/api/news?id=6cc6c5f38488037e60e08c1d2aae9752974b3b3dc318b6fd86f9fde0597446d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.",
                "category": "company",
                "datetime": 1783627020,
                "headline": "Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock."
              },
              {
                "id": 140854672,
                "url": "https://finnhub.io/api/news?id=5ab5bb83d308f4e877be54702b0f4785329be7a884587e842d83b5218288e07e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker’s market capitalization to $1.063 trillion. No other Big Pharma name has expanded its footprint ... Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma",
                "category": "company",
                "datetime": 1783621688,
                "headline": "Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma"
              },
              {
                "id": 140853483,
                "url": "https://finnhub.io/api/news?id=7f0f6609f05d4b5757e92a3c0ee70a033a95ba8a1b7a350b1878bc4ebde3b566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.",
                "category": "company",
                "datetime": 1783617360,
                "headline": "/C O R R E C T I O N -- Eli Lilly and Company/"
              },
              {
                "id": 140854673,
                "url": "https://finnhub.io/api/news?id=29953f580c8a9fc3d5c94760a243e5576cfbd9633038a5409e6067a2a5fd63fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.",
                "category": "company",
                "datetime": 1783616640,
                "headline": "Stocks Look Shaky, But This Sector is Booming (Biotech)"
              },
              {
                "id": 140853484,
                "url": "https://finnhub.io/api/news?id=a37245c725bdaa7038adeca694577bae64e2a1096e408d1811dd4be0d93626e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%",
                "category": "company",
                "datetime": 1783613908,
                "headline": "Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%"
              },
              {
                "id": 140852010,
                "url": "https://finnhub.io/api/news?id=553e10dc88f8db461878d38f0666f117101c8f854c6a22e5273fb7ce1784b80d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now",
                "category": "company",
                "datetime": 1783611325,
                "headline": "Jim Cramer Says Biotech is The Hottest Group in The Market Right Now"
              },
              {
                "id": 140852114,
                "url": "https://finnhub.io/api/news?id=18cb1deec87714a810815bec92145326d36f86f537c4507db6c6fe56c1ba3f15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.",
                "category": "company",
                "datetime": 1783605360,
                "headline": "Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?"
              },
              {
                "id": 140854329,
                "url": "https://finnhub.io/api/news?id=f85d59ff5cf636e53f4a04b2a9899cbee55215709e026bf0dbff25839923e5cd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783604108,
                "headline": "9 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140850813,
                "url": "https://finnhub.io/api/news?id=50fe695c6a36d08d65a0a18fef1e35d803ac85b36d09df2ce807f7b82ab5f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly Wins Positive Canada Recommendation, Strengthening Drug Pipeline",
                "category": "company",
                "datetime": 1783601052,
                "headline": "Eli Lilly Stock Gets a Lift After Canada Backs Eczema Drug"
              },
              {
                "id": 140850814,
                "url": "https://finnhub.io/api/news?id=05ce077906bfc530a482322e629b82e62aeb3e9fbbbbcf058e73d19af507c405",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Ebglyss received a positive recommendation that could expand public access.",
                "category": "company",
                "datetime": 1783599912,
                "headline": "Lilly Gets Canada Boost"
              },
              {
                "id": 140850815,
                "url": "https://finnhub.io/api/news?id=5be54a290529b9ace35b284e57b9ef50d322b5dd549d35120402b2d467a67c2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July",
                "category": "company",
                "datetime": 1783598459,
                "headline": "3 High Growth GLP-1 Biotech Winners to Buy in July"
              },
              {
                "id": 140849930,
                "url": "https://finnhub.io/api/news?id=ab384ad81929c67c34b3717b8f7b67d75591d4ca1323592f9ffb152c69fe419d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.",
                "category": "company",
                "datetime": 1783596600,
                "headline": "Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 3,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": -0.3,
            "source_article_count": 249,
            "discarded_article_count": 227
          },
          "sentimentPoints": 1
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.7,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.4%→8.1%)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 2941628.9,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2320276.7,
              "avg_vol_20": 2895498.35,
              "avg_vol_30": 2941628.9,
              "range_pct_10": 0.08067032694794199,
              "range_pct_20": 0.12528371890717063,
              "range_pct_30": 0.14364551271811582,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.788772744243844,
              "dist_to_20d_high": 0.051526676998946516,
              "down_shrink_days": 5,
              "breakout_level_20d": 1249.44995,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5615930871871103
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.1316970044905683,
              "turnoverUsdM": 1680.653161647794,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1110.8443,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.3,
            "take_profit_price": 1244.3234,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 5
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.263394008981137,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 37.1128,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.13
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -35.59
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1627
    },
    "kdj": {
      "d": 38.26,
      "j": 71.39,
      "k": 49.3,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 36.96
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 27155622,
      "recentSlope": 269932.2,
      "previousSlope": 631690
    },
    "rsi": 44.38,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 1222.7544,
      "position": "SAR喺價上",
      "distancePct": 3.18,
      "previousTrend": "下降"
    },
    "ma50": 1125.2808,
    "macd": {
      "macd": 12.94283714039625,
      "trend": "中性偏多",
      "signal": 19.967125370235415,
      "histogram": -7.024288229839165
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 1186.637,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.5,
      "score": 2,
      "avgVolume": 2820998,
      "currentVolume": 1418189
    },
    "derived": {
      "ma20": 1186.8755,
      "ma50": 1125.2808,
      "prevClose": 1163.01,
      "avgVolume10": 2253286,
      "avgVolume20": 2820998,
      "changePercent": 1.9,
      "avgVolumeForScore": 2820998
    },
    "ma_cross": {
      "ma20": 1186.8755,
      "ma50": 1125.2808,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 1183.485,
      "prevMa50": 1120.9192,
      "spreadPct": 5.47,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 1130.6532,
      "upper": 1243.0978,
      "position": "中間"
    },
    "rsi_short": 62.09,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.5
    }
  }
}

{
  "close": 1185.07,
  "volume": 1418189,
  "changePercent": 1.9
}